Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

EU regulator backs use of Novo’s Wegovy for obesity-related heart condition

2024 09 20T140712Z 2 LYNXMPEK8I0R9 RTROPTP 4 TOTW OBESITY

Published : 4 weeks ago, on

(Reuters) -The European Medicines Agency backed the use of Novo Nordisk’s popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday.

This marks the regulator’s second backing for a use of Wegovy beyond weight loss and further strengthens Novo’s case that the medicine has multiple health benefits.

The agency has also backed use of Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes.

Novo expects the label update for use in patients with an obesity-related common heart condition will be implemented shortly. It would allow use of the drug in patients suffering from obesity-related heart failure with preserved ejection fraction (HFpEF).

HFpEF is a condition in which heart muscles stiffen and draw in less blood. It accounts for about half of heart failure cases, with symptoms including shortness of breath and swelling in the extremities.

Data from a late-stage study showed patients lost weight after one year on Wegovy and had a 16.6-point improvement on a 100-point health scale based on a range of heart failure-related criteria.

It also improved physical limitations and exercise function in patients with the condition, Novo said.

The drug, chemically known as semaglutide, has been authorized in the European Union to treat obesity since 2022. The blockbuster drug belongs to a class of treatments known as GLP-1 agonists, which help regulate blood sugar and suppress appetite.

Novo’s U.S. rival Eli Lilly’s drug tirzepatide is also approved for weight loss in the EU. Tirzepatide has shown to cut heart failure risk by 38% in a trial of preserved ejection fraction and obesity patients.

Novo reiterated it plans to resubmit Wegovy’s data for easing heart failure in people with obesity to the U.S. Food and Drug Administration next year.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta and Krishna Chandra Eluri)

 

Jesse Pitts has been with the Global Banking & Finance Review since 2016, serving in various capacities, including Graphic Designer, Content Publisher, and Editorial Assistant. As the sole graphic designer for the company, Jesse plays a crucial role in shaping the visual identity of Global Banking & Finance Review. Additionally, Jesse manages the publishing of content across multiple platforms, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune.

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post